Blar i forfatter "Øy, Geir Frode"

Viser treff 1-7 av 7

    • Biodistribution of Poly(alkyl cyanoacrylate) Nanoparticles in Mice and Effect on Tumor Infiltration of Macrophages into a Patient-Derived Breast Cancer Xenograft 

      Pandya, Abhilash D.; Iversen, Tore Geir; Moestue, Siver Andreas; Grinde, Maria Tunset; Mørch, Ýrr Asbjørg; Snipstad, Sofie; Åslund, Andreas; Øy, Geir Frode; Kildal, Wanja; Engebråten, Olav; Sandvig, Kirsten; Skotland, Tore; Mælandsmo, Gunhild Mari (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-04-28)
      We have investigated the biodistribution and tumor macrophage infiltration after intravenous injection of the poly(alkyl cyanoacrylate) nanoparticles (NPs): PEBCA (poly(2-ethyl-butyl cyanoacrylate), PBCA (poly(n-butyl cyanoacrylate), and POCA (poly(octyl cyanoacrylate), in mice. These NPs are structurally similar, have similar PEGylation, and have previously been shown to give large variations in ...

    • Breast cancer patient-derived explant cultures recapitulate in vivo drug responses 

      Pettersen, Solveig; Øy, Geir Frode; Egeland, Eivind Valen; Juell, Siri; Engebråten, Olav; Mælandsmo, Gunhild Mari; Prasmickaite, Lina (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-02-22)
      Assessment of drug sensitivity in tumor tissue ex vivo may significantly contribute to functional diagnostics to guide personalized treatment of cancer. Tumor organoid- and explant-cultures have become attractive tools towards this goal, although culturing conditions for breast cancer (BC) tissue have been among the most challenging to develop. Validation of possibilities to detect concordant responses ...

    • Fibroblast growth factor 2 conjugated with monomethyl auristatin E inhibits tumor growth in a mouse model 

      Krzyscik, Mateusz Adam; Zakrzewska, Malgorzata; Sørensen, Vigdis; Øy, Geir Frode; Bruheim, Skjalg; Haugsten, Ellen Margrethe; Mælandsmo, Gunhild Mari; Wiedlocha, Antoni; Otlewski, Jacek (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-09-20)
      Worldwide, cancer is the second leading cause of death. Regardless of the continuous progress in medicine, we still do not have a fully effective anti-cancer therapy. Therefore, the search for new targeted anti-cancer drugs is still an unmet need. Here, we present novel protein–drug conjugates that inhibit tumor growth in a mouse model of human breast cancer. We developed conjugates based on fibroblast ...

    • Liver X receptors induce antiproliferative effects in basal-like breast cancer 

      Haugen, Mads; von der Lippe Gythfeldt, Hedda; Egeland, Eivind Valen; Svartdal Normann, Lisa; Pandya, Abhilash D.; Vedin, Lise-Lotte; Juell, Siri; Tenstad, Ellen; Øy, Geir Frode; Kristian, Alexandr; Marangoni, Elisabetta; Sørlie, Therese; Steffensen, Knut Rune; Mælandsmo, Gunhild Mari; Engebråten, Olav (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-06-21)
      Liver X receptors (LXRs) are nuclear transcription factors important in the regulation of cholesterol transport, and glucose and fatty acid metabolism. The antiproliferative role of LXRs has been studied in a variety of malignancies and may represent a therapeutic opportunity in cancers lacking targeted therapies, such as triple-negative breast cancer. In this study, we investigated the impact of ...

    • Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma 

      Fiorito, Elisa; Szybowska, Patrycja Maria; Haugsten, Ellen Margrethe; Kostas, Michal Janusz; Øy, Geir Frode; Wiedlocha, Antoni; Singh, Sachin Kumar; Nakken, Sigve; Mælandsmo, Gunhild Mari; Fletcher, Jonathan A.; Meza, Leonardo Zepeda; Wesche, Jørgen (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-09-12)
      Background: Rhabdomyosarcoma (RMS) is a paediatric cancer driven either by fusion proteins (e.g., PAX3-FOXO1) or by mutations in key signalling molecules (e.g., RAS or FGFR4). Despite the latter providing opportunities for precision medicine approaches in RMS, there are currently no such treatments implemented in the clinic.<p> <p>Methods: We evaluated biologic properties and targeting strategies ...

    • Targeting AXL and the DNA damage response pathway as a novel therapeutic strategy in melanoma 

      Karlsen, Karine Flem; McFadden, Erin; Omar, Nasrin; Haugen, Mads Haugland; Øy, Geir Frode; Ryder, Truls; Gullestad, Hans Petter; Hermann, Robert; Mælandsmo, Gunhild Mari; Flørenes, Vivi Ann (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-12-23)
      Receptor tyrosine kinase AXL is found upregulated in various types of cancer, including melanoma, and correlates with an aggressive cancer phenotype, inducing cell proliferation and epithelial-to-mesenchymal transition. Additionally, AXL has recently been linked to chemotherapy resistance and inhibition of AXL is found to increase DNA damage and reduce expression of DNA repair proteins. In light of ...

    • A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases 

      Flørenes, Vivi Ann; Flem-Karlsen, Karine; McFadden, Erin; Bergheim, Inger Riise; Nygaard, Vigdis; Nygård, Vegard Mokleiv; Farstad, Inger Nina; Øy, Geir Frode; Emilsen, Elisabeth; Fleten, Karianne Giller; Ree, Anne Hansen; Flatmark, Kjersti; Gullestad, Hans Petter; Hermann, Robert; Ryder, Truls; Wernhoff, Patrik; Mælandsmo, Gunhild Mari (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-05-13)
      Although clinical management of melanoma has changed considerably in recent years, intrinsic treatment resistance remains a severe problem and strategies to design personal treatment regimens are highly warranted. We have applied a three-dimensional (3D) <i>ex vivo</i> drug efficacy assay, exposing disaggregated cells from 38 freshly harvested melanoma lymph node metastases and 21 patient derived ...